1. Home
  2. PRTA vs WSHP Comparison

PRTA vs WSHP Comparison

Compare PRTA & WSHP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.61

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

WSHP

WeShop Holdings Limited Class A Ordinary Shares

N/A

Current Price

$5.69

Market Cap

487.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTA
WSHP
Founded
2012
2021
Country
Ireland
British Virgin Islands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
539.9M
487.8M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
PRTA
WSHP
Price
$10.61
$5.69
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
462.3K
274.3K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$814,000.00
N/A
Revenue This Year
$1,111.38
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.32
$4.95
52 Week High
$11.69
$250.00

Technical Indicators

Market Signals
Indicator
PRTA
WSHP
Relative Strength Index (RSI) 64.85 33.54
Support Level $9.69 $4.95
Resistance Level $10.90 $117.73
Average True Range (ATR) 0.41 1.08
MACD 0.11 1.13
Stochastic Oscillator 95.21 25.59

Price Performance

Historical Comparison
PRTA
WSHP

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About WSHP WeShop Holdings Limited Class A Ordinary Shares

WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the Company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.

Share on Social Networks: